Could playing a video game improve your child's ADHD symptoms? That's the promise fueling a surge in digital therapeutics and other emerging tech tools designed to help individuals manage their ADHD. Virtual reality games with stimuli to punch or avoid. Video games requiring problem-solving strategies to save the galaxy from a meteor storm. A to-do app designed to help kids follow routines.

Digital health is defined as the space where digital technologies, daily life, and health care intersect. The objective of digital health is to enhance the efficiency of healthcare delivery and make medicine more individualised and precise. Information and communication technologies are used to help address the health problems faced by people undergoing treatment. The interconnectedness of health systems development, improved use of computational analysis, smart devices, and communication media are the techniques and tools used in digital health to aid clinicians and their clients with managing illnesses and health conditions while simultaneously promoting good health and well being. Generally, digital health is concerned about the development of interconnected health systems to improve the use of computational technologies, smart devices, computational analysis techniques, and communication media to aid healthcare professionals and their clients manage illnesses and health risks, as well as promote health and wellbeing.

The Digital Therapeutics Alliance defines DTx as products that "deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease." The top 10 most funded Digital Therapeutic (DTx) companies have collectively raised over $2B in funding, and digital health M&A is significantly bigger. As of December 2020, the top 20 digital health mergers and acquisitions totaled $50B. Back in 2017 at SXSW, ABC's "Shark Tank" investor Mark Cuban predicted the first person with a Net Worth of over $1T will be working in Artificial Intelligence. "… the world's first trillionaires are going to come from somebody who masters AI and all its derivatives and applies it in ways we never thought of … " Mark Cuban Most of the current digital therapeutics companies are focused on diseases or disorders with a behavioral component that can be leveraged to improve health.

Boston and San Francisco, January 7, 2020 – Pear Therapeutics, Inc., the leader in Prescription Digital Therapeutics (PDTs), announced today that it has entered into agreements with multiple technology innovators, including Firsthand Technology, Inc., leading researchers from the Karolinska Institute in Sweden, Cincinnati Children's Hospital Medical Center, Winterlight Labs, Inc., and NeuroLex Laboratories, Inc. These new agreements continue to bolster Pear's PDT platform, by adding to its library of digital biomarkers, machine learning algorithms, and digital therapeutics. Pear's investment in these cutting-edge technologies further supports its strategy to create the broadest and deepest toolset for the development of PDTs that redefine standard of care in a range of therapeutic areas. With access to these new technologies, Pear is positioned to develop PDTs in new disease areas, while leveraging machine learning to personalize and improve its existing PDTs. "We are excited to announce these agreements, which expand the leading PDT platform," said Corey McCann, M.D., Ph.D., President and CEO of Pear.

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Pear Therapeutics, Inc., the leader in Prescription Digital Therapeutics (PDTs), announced today that it has entered into agreements with multiple technology innovators, including Firsthand Technology, Inc., leading researchers from the Karolinska Institute in Sweden, Cincinnati Children's Hospital Medical Center, Winterlight Labs, Inc., and NeuroLex Laboratories, Inc. These new agreements continue to bolster Pear's PDT platform, by adding to its library of digital biomarkers, machine learning algorithms, and digital therapeutics. Pear's investment in these cutting-edge technologies further supports its strategy to create the broadest and deepest toolset for the development of PDTs that redefine standard of care in a range of therapeutic areas. With access to these new technologies, Pear is positioned to develop PDTs in new disease areas, while leveraging machine learning to personalize and improve its existing PDTs. "We are excited to announce these agreements, which expand the leading PDT platform," said Corey McCann, M.D., Ph.D., President and CEO of Pear.